title: Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes.
abstract: Interleukin-1β Interleukin-1β (IL-1β) is a key regulator of the body's inflammatory response and is produced after infection, injury, and an antigenic challenge. Cloned in 1984, the single polypeptide IL-1β has been shown to exert numerous biological effects. It plays a role in various diseases, including autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases, and Type 1 diabetes, as well as in diseases associated with metabolic syndrome such as atherosclerosis, chronic heart failure, and Type 2 diabetes. The macrophage is the primary source of IL-1β, but epidermal, epithelial, lymphoid, and vascular tissues also synthesize IL-1. Recently, IL-1β production and secretion have also been reported from pancreatic islets. Insulin-producing β-cells β-cells within the pancreatic islets are specifically prone to IL-β-induced destruction and loss of function. Macrophage-derived IL-1β production in insulin-sensitive organs leads to the progression of inflammation inflammation and induction of insulin resistance in obesity. This chapter explains the mechanisms involved in the inflammatory response during diabetes progression with specific attention to the IL-1β signal effects influencing insulin action and insulin secretion insulin secretion . We highlight recent clinical studies, rodent and in vitro experiments with isolated islets using IL-1β as a potential target for the therapy of Type 2 diabetes.
authors.affiliation: Centre for Biomolecular Interactions Bremen, University of Bremen, Leobener Straße NW2, Room B2080, 330440, 28334, 28359, Bremen, Germany. kmaedler@uni-bremen.de
authors.forename: Kathrin
authors.initials: K
authors.lastname: Maedler
authors.forename: Gitanjali
authors.initials: G
authors.lastname: Dharmadhikari
authors.forename: Desiree M
authors.initials: DM
authors.lastname: Schumann
authors.forename: Joachim
authors.initials: J
authors.lastname: Størling
mesh_terms: D017667:Adipocytes / Q000502:physiology; D000818:Animals; D001921:Brain / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D050417:Insulin-Secreting Cells / Q000502:physiology; D053583:Interleukin-1beta / Q000378:metabolism / Q000502:physiology; D007378:Interleukins / Q000037:antagonists & inhibitors*; D008099:Liver / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000188:drug therapy*; D051379:Mice; D009765:Obesity / Q000503:physiopathology; D015398:Signal Transduction / Q000502:physiology
chemical_list: D053583:Interleukin-1beta; D007378:Interleukins